Somatic mutations of MLL4/COMPASS induce cytoplasmic localization providing molecular insight into cancer prognosis and treatment.
cancer biomarker
chromatin modifiers
epigenetics
mutation
treatment
Journal
Proceedings of the National Academy of Sciences of the United States of America
ISSN: 1091-6490
Titre abrégé: Proc Natl Acad Sci U S A
Pays: United States
ID NLM: 7505876
Informations de publication
Date de publication:
26 Dec 2023
26 Dec 2023
Historique:
medline:
19
12
2023
pubmed:
19
12
2023
entrez:
19
12
2023
Statut:
ppublish
Résumé
Cancer genome sequencing consortiums have recently catalogued an abundance of somatic mutations, across a wide range of human cancers, in the chromatin-modifying enzymes that regulate gene expression. Defining the molecular mechanisms underlying the potentially oncogenic functions of these epigenetic mutations could serve as the basis for precision medicine approaches to cancer therapy. MLL4 encoded by the
Identifiants
pubmed: 38113256
doi: 10.1073/pnas.2310063120
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2310063120Subventions
Organisme : HHS | NIH | NCI | Center for Biomedical Informatics and Information Technology, National Cancer Institute (CBIIT)
ID : R35-CA197569
Déclaration de conflit d'intérêts
Competing interests statement:J.J.M.: Consultant: Merck, AstraZeneca, Incyte, Janssen, BMS, UroGen, Prokarium, Imvax, Pfizer, Seagen/Astellas, Compensation for talks/educational courses: AUA, OncLive, Olympus, UroToday, Clinical Trials: SWOG, Genentech, Merck, AstraZeneca, Incyte.